MODALITIES

Peptides and vaccines as programmable modalities-chosen by target biology, delivery, immune logic, and translation burden.

Agemica advances peptides and vaccines as programmable modalities for aging driven disease, selecting each format by target biology, delivery burden, immune logic, and the evidence required for clinical translation.

Why peptides

Peptides bridge chemical synthesis and cell-made biologics.

Modern therapeutics fall into three broad modality families-small molecules, peptides, and large biologics-each with different manufacturing physics and trade-offs. Agemica works in the peptide band: large enough for high-specificity receptor engagement, small enough to manufacture as discrete chemistry-so ranked sequences can become synthesized, testable candidates without standing up recombinant protein production.

Peptides are short amino-acid chains-typically on the order of tens of residues-built stepwise with protecting-group chemistry. Today’s workflows lean on Fmoc solid-phase peptide synthesis (SPPS): coupling on resin, wash-away workup, and routes that scale to pharmaceutical purity. That is the operational link for Agemica-sequence edits proposed in software are the same residues encoded in synthesis, which keeps the AI→lab loop honest and fast.

  • Small molecules - Low molecular weight (often under ~900 Da), frequently oral and membrane-permeable; limited binding surface area can mean noisier target engagement and meaningful off-target liability.
  • Peptides - Large enough to engage receptors with biologic-like precision, yet produced by automated SPPS rather than cell culture. Agemica uses this intersection: predictable chemistry from prediction to vial on days-to-weeks cycles.
  • Biologics - Antibodies and recombinant proteins offer exceptional surfaces for complex targets, but manufacturing is cell-based, costly, and typically injectable-trade-offs peptides sidestep when biology permits a designed, synthetic scaffold.
Two products from one substrate

Therapeutic peptides - and peptide vaccines.

Therapy

Combination therapies - approved or clinically characterized drugs selected to target shared cancer mechanisms.

Vaccine

Peptide vaccines - multi-epitope antigens designed to evoke a durable, selective immune response. Our platform models scale to 300+ disease targets from a single design framework.

Next · Platform
Vaccine Design AI
Continue
Next · Research
Cancer cell death
Continue